Cutaneous Squamous Cell Carcinoma Clinical Trial
Official title:
ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of your tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
Primary Objective: Determine the feasibility of three doses of atezolizumab prior to surgery in patients with advanced cutaneous squamous cell carcinoma Secondary Objectives: - Assess response rates to neoadjuvant atezolizumab Objective response rate following completion of neoadjuvant therapy based on RECIST 1.1 criteria oPathological response rate (major and complete pathological response) in final surgical resection specimen - Assess change in surgical margins or vital structures preserved following neoadjuvant treatment - Assess safety and tolerability of neoadjuvant atezolizumab ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
| Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT04502888 -
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
|
Phase 1 | |
| Recruiting |
NCT05377905 -
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05888844 -
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04050436 -
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
|
Phase 2 | |
| Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
| Completed |
NCT04616196 -
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05108090 -
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
|
N/A | |
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04975152 -
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT01500954 -
Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma
|
N/A | |
| Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04339062 -
Cemiplimab in AlloSCT/SOT Recipients With CSCC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05565417 -
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04664582 -
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
|
N/A | |
| Not yet recruiting |
NCT06384820 -
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
|
Phase 2 | |
| Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT06046625 -
Needs and Preferences of Patients With Head-neck Cutaneous SCC
|